PMC3155273_01
The right fundus showed subretinal hemorrhage at inferotemporal fovea and tilted disc with inferotemporal peripapillary atrophy.
opth-5-1079f1.jpg
PMC3155273_01_opth-5-1079f1.jpg
f1-opth-5-1079
The right fundus showed chorioretinal atrophy at the posterior pole, with a subretinal hemorrhage at the inferotemporal fovea (Figure 1).
The FFA of the right eye showed the presence of choroidal neovascularisation with the evidence of hyperfluoresence area at the fovea which increased in intensity and size throughout the phase.
opth-5-1079f2.jpg
PMC3155273_01_opth-5-1079f2.jpg
f2-opth-5-1079
Fundus fluorescein angiography of the right eye revealed a hyperfluorescent area at the fovea which was increasing in intensity and size (Figure 2).
Right fundus showed the subretinal hemorrhage became less dense and reducing in size at one week post intravitreal ranibizumab.
opth-5-1079f3.jpg
PMC3155273_01_opth-5-1079f3.jpg
f3-opth-5-1079
The intraocular pressure was normal, and no complications, such as intraocular infection, retinal tear, or vitreous hemorrhage was seen. The fundus showed that the subretinal hemorrhage had become less dense and was reducing in size (Figure 3).
Repeated FFA showed no more features of choroidal neovascularisation in right eye.
opth-5-1079f4.jpg
PMC3155273_01_opth-5-1079f4.jpg
f4-opth-5-1079
At 10-week follow-up, visual acuity improved to 6/7.5 with glasses, and repeat fundus fluorescein angiography showed the absence of CNV (Figure 4).